Notice: Images are for illustration only and may not reflect the exact product you receive. Brand-name medications may look different depending on their country of origin—Canadian versions, for example, often include a "PR" symbol on the packaging. Rest assured, the medication, dosage, and active ingredients will be exactly as prescribed. Canada Pharmacy Store is committed to your health and safety, and we work only with licensed pharmacies to ensure you receive trusted, high-quality medication every time.
General Medication Fact Sheet for Xospata
| Field | Information |
|---|---|
| Medication Name | Xospata |
| Generic Name | Gilteritinib |
| Boxed/Label Warning | May cause differentiation syndrome and QT prolongation. |
| Purpose | Treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation. |
| Mechanism of Action | FLT3 inhibitor; inhibits FLT3 receptor tyrosine kinase, leading to apoptosis in FLT3-mutated AML cells. |
| Dosage Forms | Oral tablets |
| Available Strengths | 40 mg |
| Dosage Frequency | 120 mg once daily, until disease progression or unacceptable toxicity. |
| Common Side Effects | Nausea, fatigue, fever (pyrexia), edema, rash, pneumonia, increased transaminases, diarrhea, dyspnea. |
| Serious Side Effects | Differentiation syndrome, QT prolongation, posterior reversible encephalopathy syndrome (PRES), pancreatitis. |
| Drug Interactions | Strong CYP3A inhibitors and inducers, drugs that prolong the QT interval. |
| Important Notes | Monitor for signs and symptoms of differentiation syndrome, QT prolongation, and pancreatitis. Assess liver function before starting and during treatment. |
| Storage | Store at room temperature away from moisture and light. |
| Missed Dose | If a dose is missed by more than 12 hours, skip the dose and take the next dose at the regularly scheduled time. Do not double the dose. |
| Alternatives | Chemotherapy regimens (e.g., cytarabine and daunorubicin), Midostaurin, Sorafenib. |
Xospata Alternatives
| Medication | Mechanism of Action | Notes |
|---|---|---|
| Chemotherapy regimens (e.g., cytarabine and daunorubicin) | Cytotoxic agents that kill rapidly dividing cells, including leukemia cells. | Standard treatment for AML; various regimens exist depending on patient and disease characteristics. |
| Midostaurin (Rydapt) | FLT3 inhibitor, multi-kinase inhibitor | Used in newly diagnosed AML with FLT3 mutations, in combination with chemotherapy. |
| Sorafenib (Nexavar) | Multi-kinase inhibitor, including FLT3 | May be used in certain AML cases, especially when other FLT3 inhibitors are not appropriate. |
Xospata Side Effects
| Common Side Effects | Serious Side Effects |
|---|---|
| Nausea | Differentiation syndrome |
| Fatigue | QT prolongation |
| Fever (Pyrexia) | Posterior Reversible Encephalopathy Syndrome (PRES) |
| Edema | Pancreatitis |
| Rash | Pneumonia |
| Diarrhea | Increased Liver Enzymes |
| Dyspnea (Shortness of breath) | Tumor Lysis Syndrome |
Xospata Dosage Guide
| Condition | Starting Dose | Maintenance Dose | Administration Notes |
|---|---|---|---|
| Relapsed or Refractory AML with FLT3 mutation | 120 mg daily | 120 mg daily | Administer orally once daily until disease progression or unacceptable toxicity. May be taken with or without food. |
